BioPharmSignal logoBioPharmSignal

Biotech News

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

Tempest Therapeutics (TPST)Tempest TherapeuticsConference / presentation

Presentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19/BCMA CAR-T therapy candidate TPST-2003 Results support clinical benefit of parallel-structure dual-targeting CAR architecture in patients with relapsed/refractory multiple myeloma Data further

Open original release

Related news

TPSTTempest Therapeutics2026-05-06 11:00 EST

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

TPSTTempest Therapeutics2026-05-14 20:15 EST

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

REPLReplimune Group2026-05-31 12:00 EST

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

LYELLyell Immunopharma2026-06-01 12:00 EST

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

RVMDRevolution Medicines2026-05-21 20:05 EST

Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation

ERASErasca2026-05-27 12:00 EST

Erasca to Present at the Jefferies Global Healthcare Conference

INBXInhibrx2026-05-08 20:00 EST

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC

ERASErasca2026-05-06 12:00 EST

Erasca to Present at the Bank of America Securities Health Care Conference

KYMRKymera2026-05-27 11:00 EST

Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

KYMRKymera2026-05-15 11:00 EST

Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses

View all latest news

Tempest Therapeutics

Tempest Therapeutics is an oncology company focused on small molecules and immunotherapy combinations for difficult cancers. Its investment case is driven by the idea that combination strategies can unlock differentiated responses in solid tumors.

Recent company news

TPSTTempest Therapeutics2026-05-29 12:00 EST

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

TPSTTempest Therapeutics2026-05-14 20:15 EST

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

TPSTTempest Therapeutics2026-05-06 11:00 EST

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

TPSTTempest Therapeutics2026-04-29 12:00 EST

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

TPSTTempest Therapeutics2026-04-22 12:00 EST

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Stock data

Close
0.93 USD
Market cap
19.4M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States